Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

79.99B

Market cap79.99B

Price-Earnings ratio

18.07

Price-Earnings ratio18.07

Dividend yield

0.48%

Dividend yield0.48%

Average volume

601.78K

Average volume601.78K

High today

$761.73

High today$761.73

Low today

$747.77

Low today$747.77

Open price

$749.30

Open price$749.30

Volume

473.68K

Volume473.68K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$476.49

52 Week low$476.49

Stock Snapshot

With a market cap of 79.99B, Regeneron(REGN) trades at $756.73. The stock has a price-to-earnings ratio of 18.07 and currently yields dividends of 47.8%.

On 2026-03-26, Regeneron(REGN) stock traded between a low of $747.77 and a high of $761.73. Shares are currently priced at $756.73, which is +1.2% above the low and -0.7% below the high.

The Regeneron(REGN)'s current trading volume is 473.68K, compared to an average daily volume of 601.78K.

During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.

REGN News

Simply Wall St 1d

The Bull Case For Regeneron Pharmaceuticals Could Change Following New Japanese Dupixent BP Approval

Regeneron Pharmaceuticals and Sanofi recently received Japanese Ministry of Health, Labour and Welfare approval for Dupixent as the first targeted treatment for...

TipRanks 3d

Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare, or MHLW, in Japan has approved Dupixent for the treatment of adults...

Investor's Business Daily 3d

How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug

Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' 3/20/2026 Rhythm Pharmaceuticals stock ultimately closed down Friday,...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

23.3%

Sell

More REGN News

Simply Wall St 4d

Assessing Regeneron Pharmaceuticals Valuation After Recent Weak Share Momentum And Franchise Outlook

Advertisement Recent performance context Regeneron Pharmaceuticals (REGN) has recently drawn investor attention after a period of weaker share performance, wi...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

MercadoLibre

Constellation Brands

abrdn Physical Precious M…

ServiceNow

Cipher Mining

Palo Alto Networks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.